A Single Center, Single-blind, Randomized, Dose-escalation, Parallel, Placebo and Active-controlled, Single Dose, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults
Latest Information Update: 22 Nov 2024
At a glance
- Drugs Ropivacaine sustained release G2GBIO (Primary) ; Ropivacaine
- Indications Postoperative pain
- Focus Adverse reactions
- Sponsors G2GBIO
Most Recent Events
- 18 Nov 2024 The protocol has been amended to increase in the number of arm size for a cohorts.
- 18 Nov 2024 Status changed from recruiting to completed.
- 31 Oct 2023 New trial record